Compass Therapeutics, Inc. (CMPX)
| Market Cap | 437.61M -15.5% |
| Revenue (ttm) | n/a |
| Net Income | -73.45M |
| EPS | -0.40 |
| Shares Out | 180.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,445,009 |
| Open | 2.510 |
| Previous Close | 2.530 |
| Day's Range | 2.410 - 2.520 |
| 52-Week Range | 1.610 - 6.880 |
| Beta | 0.82 |
| Analysts | Strong Buy |
| Price Target | 8.92 (+267.08%) |
| Earnings Date | Aug 6, 2026 |
About CMPX
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; C... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for CMPX stock is "Strong Buy." The 12-month stock price target is $8.92, which is an increase of 267.08% from the latest price.
News
Compass Therapeutics price target raised to $7 from $4 at Leerink
Leerink raised the firm’s price target on Compass Therapeutics (CMPX) to $7 from $4 and keeps an Outperform rating on the shares.
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior t...
Compass Therapeutics Earnings release: Q2 2026
Compass Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Compass Therapeutics Quarterly report: Q2 2026
Compass Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...
Compass Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Four oncology assets are advancing, with lead drug tovecimig showing strong efficacy in BTC and moving toward FDA submission. Multiple clinical and regulatory catalysts are expected in the next year, supported by a cash runway into 2028.
Compass Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Lead oncology asset tovecimig demonstrated significant efficacy in biliary tract cancer, with plans for FDA submission and further studies underway. Promising early results from PD-1/PD-L1 bispecific and CD137 agonist programs, with multiple data updates expected later this year.
Compass Therapeutics to Participate in Upcoming June Investor Events
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...
Compass Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum
Significant PFS and ORR results for tovecimig support a planned BLA submission, with FDA feedback expected by Labor Day and confirmatory study designs under consideration. CTX-8371 data will debut at ASCO, and strong cash reserves support ongoing clinical and pipeline expansion.
Compass Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
The company highlighted strong phase II/III data for its lead bispecific antibody in biliary tract cancer, with plans for FDA submission and significant commercial potential. Pipeline updates include promising early results for PD-1/PD-L1 and PD-1/VEGF bispecifics, and a new phase II study for a CD137 agonist.
Compass Therapeutics to Participate in Upcoming May Investor Events
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...
Compass Therapeutics reports Q1 EPS (10c), consensus (10c)
“We recently announced positive data from our Phase 2/3 study of tovecimig and look forward to meeting with the FDA before filing a BLA later this year. Most patients with…
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...
Compass Therapeutics Earnings release: Q1 2026
Compass Therapeutics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Compass Therapeutics Quarterly report: Q1 2026
Compass Therapeutics has published its Q1 2026 quarterly earnings report on May 5, 2026.
Compass Therapeutics Proxy statement: Proxy filing
Compass Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Compass Therapeutics Proxy statement: Proxy filing
Compass Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Compass Therapeutics price target lowered to $7 from $13 at Canaccord
Canaccord lowered the firm’s price target on Compass Therapeutics (CMPX) to $7 from $13 and keeps a Buy rating on the shares. The firm said Tovecimig+paclitaxel clearly improves progression-free survi...
Compass Therapeutics downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Sean McCutcheon downgraded Compass Therapeutics (CMPX) to Market Perform from Outperform with no price target after Compass disclosed survival outcomes from COMPANION-002, the Ph...
Compass Therapeutics price target lowered to $6 from $12 at Stifel
Stifel lowered the firm’s price target on Compass Therapeutics (CMPX) to $6 from $12 and keeps a Buy rating on the shares. The firm believes event-driven COMPANION-002 secondary endpoint data…
Compass Therapeutics selloff ‘an over-reaction,’ says Jefferies
Jefferies believes the 63% selloff in Compass Therapeutics (CMPX) is “an over-reaction” given the totality of the company’s data and the biliary tract cancer market opportunity. The key focus is…
Leerink says Compass data supports path forward for tovecimig in 2L BTC
Leerink notes that Compass Therapeutics (CMPX) announced progression free survival and overall survival results for tovecimig in second line biliary tract cancer from the randomized COMPANION-002 stud...
Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Compass Therapeutics, Inc. (NASDAQ: CMPX). The investigation focuses on C...
H.C. Wainwright keeps Buy rating on Compass Therapeutics after data
After Compass Therapeutics (CMPX) announced key secondary endpoints findings, including progression free survival and overall survival, from its COMPANION-002 randomized Phase 2/3 study in patients wi...